Research programme: TBK1/IKKe inhibitors - Domainex

Drug Profile

Research programme: TBK1/IKKe inhibitors - Domainex

Latest Information Update: 16 Jul 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Domainex
  • Class Small molecules
  • Mechanism of Action I-kappa B kinase inhibitors; TBK1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Chronic obstructive pulmonary disease
  • Research Cancer; Inflammation

Most Recent Events

  • 09 Jul 2014 Preclinical trials in Chronic obstructive pulmonary disease in United Kingdom (PO)
  • 07 Apr 2014 This programme remains available for licensing as of 07 Apr 2014. http://www.domainex.co.uk/
  • 07 Apr 2014 Early research in Chronic obstructive pulmonary disease in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top